Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
NCT02036476Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in Merkel cell carcinoma (MCC), sponsored by Dana-Farber Cancer Institute. Started Feb 2014; status: terminated.
02
Drugs
cabozantinib
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT02036476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036476.